Rehmann Capital Advisory Group boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 7.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,291 shares of the exchange traded fund’s stock after buying an additional 345 shares during the quarter. Rehmann Capital Advisory Group’s holdings in SPDR S&P Biotech ETF were worth $477,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of XBI. Golden State Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF during the 4th quarter worth about $29,000. Kohmann Bosshard Financial Services LLC bought a new stake in SPDR S&P Biotech ETF in the fourth quarter worth approximately $29,000. Avior Wealth Management LLC lifted its stake in SPDR S&P Biotech ETF by 393.6% in the fourth quarter. Avior Wealth Management LLC now owns 385 shares of the exchange traded fund’s stock valued at $35,000 after buying an additional 307 shares during the period. Lee Danner & Bass Inc. bought a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth approximately $38,000. Finally, Bank of Jackson Hole Trust bought a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth approximately $43,000.
SPDR S&P Biotech ETF Stock Down 0.5 %
NYSEARCA:XBI opened at $82.50 on Friday. SPDR S&P Biotech ETF has a twelve month low of $66.66 and a twelve month high of $105.47. The company has a fifty day moving average of $81.76 and a 200-day moving average of $90.10. The firm has a market capitalization of $5.24 billion, a P/E ratio of 11.47 and a beta of 1.00.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- The Most Important Warren Buffett Stock for Investors: His Own
- The Most Inspiring Small Businesses of 2025 [Survey]
- How to Buy Cheap Stocks Step by Step
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- Business Services Stocks Investing
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.